BSP:H1ZN34 (Ireland)  
Horizon Therapeutics PLC logo

Horizon Therapeutics PLC

R$ 41.85 (-0.26%) Nov 28
P/E:
31.97
P/B:
3.57
Market Cap:
R$ 94.84B ($ 17.95B)
Enterprise V:
R$ 97.87B ($ 18.53B)
Volume:
102.00
Avg Vol (2M):
147.00
Also Trade In:
Volume:
102.00
Market Cap R$:
94.84B
Market Cap $:
17.95B
PE Ratio:
31.97
Avg Vol (2-Month):
147.00
Enterprise Value R$:
97.87B
Enterprise Value $:
18.53B
PB Ratio:
3.57
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company has two reportable segments: orphan and inflammation. Orphan segment consists of medicines such as TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, UPLIZNA, BUPHENYL, and QUINSAIR. Inflammation segment consists of PENNSAID 2%, DUEXIS, RAYOS, and VIMOVO. It generates the vast majority of its revenue from the United States.
Name Current Vs Industry Vs History
Cash-To-Debt 0.84
Equity-to-Asset 0.56
Debt-to-Equity 0.51
Debt-to-EBITDA 2.42
Interest Coverage 8.45
Piotroski F-Score 6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.74
Distress
Grey
Safe
Beneish M-Score -2.97
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 57.97
9-Day RSI 64.99
14-Day RSI 67.09
6-1 Month Momentum % -24.7
12-1 Month Momentum % -41.71

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.96
Quick Ratio 3.74
Cash Ratio 2.5
Days Inventory 85.9
Days Sales Outstanding 67.3
Days Payable 15.74

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -10.4

Financials (Next Earnings Date:2023-03-01 Est.)

BSP:H1ZN34's 30-Y Financials

Guru Trades

See Details
To
Not Enough Data to Display

Insider Trades

See Details
To
Not Enough Data to Display

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
Not Enough Data to Display

Performance

Dividend
Log
To
Not Enough Data to Display

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Not Enough Data to Display

Valuation Box

Year:
Not Enough Data to Display

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil R$) 19,418.098
EPS (TTM) (R$) 1.281
Beta 0
Volatility % 37.42
14-Day RSI 67.09
14-Day ATR (R$) 0.706638
20-Day SMA (R$) 39.3415
12-1 Month Momentum % -41.71
52-Week Range (R$) 29.85 - 62.02
Shares Outstanding (Mil) 2,266.21

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Horizon Therapeutics PLC Filings

Document Form Filing Date
No Filing Data

Horizon Therapeutics PLC Analysis

Share your research